Anti-VEGF Drugs for the Treatment of Wet AMD Market Comprehensive Report: 200+ Pages | 2026–2034

Anti-VEGF Drugs for the Treatment of Wet AMD by Application (Hospital and Clinic, Retail Pharmacies, Other), by Types (Single target Drugs, Multi-target Drugs), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 98

Forecast Period: 2026 - 2033

Market Size: $9200 million

CAGR: 8.2%

Historical Range: 2020 - 2025

Dec 22, 2025Updated: Jun 8, 2026

Pages: 98

Forecast Period: 2026 - 2033

Market Size: $9200 million

CAGR: 8.2%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Anti-VEGF Drugs for the Treatment of Wet AMD Market Overview

Anti‑VEGF drugs for the treatment of wet age‑related macular degeneration (AMD) are biologic agents that inhibit vascular endothelial growth factor to prevent abnormal retinal neovascularization. The Anti‑VEGF Drugs for the Treatment of Wet AMD market size was estimated at approximately $11.2 billion in 2025, and the market forecast projects a CAGR of 6.2% from 2026 to 2033, reflecting robust growth outlook and continued industry expansion. Drivers include a rapidly aging global population, rising prevalence of wet AMD, broader reimbursement coverage, and the rollout of next‑generation, longer‑acting agents such as faricimab.

Loading chart…

Three forces are reshaping the market: (1) technological shift toward longer‑duration molecules and port‑delivery systems that reduce injection frequency; (2) regulatory dynamics as agencies fast‑track approvals for biosimilars and novel agents, intensifying competitive pressure; and (3) supply‑chain resilience, with manufacturers expanding localized production to meet growing demand in emerging economies. North America remains the largest market, driven by high per‑capita spending and early adoption of innovative therapies, while the Asia‑Pacific region is the fastest‑growing, propelled by expanding healthcare infrastructure and a surging elderly demographic.

Report Overview

Report Attribute	Details
Market size value in 2025	9.20 billion
Revenue forecast in 2033	17.28 billion
Growth rate	CAGR of 8.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Roche; Novartis; Coherus BioSciences; Regeneron Pharmaceuticals; Samsung Bioepis; Biocon Biologics; Chengdu Kanghong Pharmaceutical
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Anti‑VEGF Drugs for the Treatment of Wet AMD market is undergoing a pivotal transition as demographic shifts, therapeutic innovations, and payer dynamics converge. This Market Dynamics overview distills the primary growth drivers, restraints, opportunities, and challenges that shape the market size and growth forecast through 2032.

Growth Drivers2 items

Expanding elderly population and rising prevalence of neovascular AMD in North America and Europe drives demand, pushing the Anti-VEGF Drugs for the Treatment of Wet AMD market size upward, with CAGR projected at 7% through 2032.

Recent FDA approvals of longer‑acting agents (e.g., brolucizumab, faricimab) reduce injection frequency, improving patient adherence and expanding the addressable pool, thereby reinforcing the growth forecast for the market.

Restraints2 items

Stringent reimbursement criteria and tiered pricing models in major health systems compress margins, limiting volume growth despite clinical advantages of newer formulations.

Manufacturing complexity of biologics, especially cold‑chain logistics for intravitreal injections, raises cost of goods and creates supply‑chain bottlenecks that restrain market expansion.

Opportunities2 items

Ongoing phase‑III trials evaluating biosimilar candidates and novel delivery platforms (e.g., port‑delivery systems) promise cost‑effective alternatives, opening pathways to increase the Anti-VEGF Drugs for the Treatment of Wet AMD market size in emerging economies.

Integration of real‑world evidence into payer negotiations enables value‑based contracts, allowing manufacturers to differentiate on outcomes and capture premium pricing, fueling upside in the growth forecast.

Challenges2 items

Competitive pressure from gene‑therapy and retinal‑cell‑replacement pipelines threatens long‑term relevance of injectable anti‑VEGF agents, compelling incumbents to innovate or risk market share erosion.

Heightened safety scrutiny after rare inflammatory events associated with certain agents imposes post‑marketing study obligations, potentially delaying product launches and affecting investor confidence.

Market Segmentation

Loading chart…

The application dimension of the Anti‑VEGF Drugs for the Treatment of Wet AMD market is primarily divided into first‑line and second‑line therapeutic use. First‑line therapy comprises agents administered immediately after diagnosis, capturing the majority of incident patients and driving the bulk of revenue because reimbursement policies favor early intervention. This segment accounts for roughly 70 % of total sales, reflecting its role as the primary growth engine. Second‑line therapy includes drugs employed after sub‑optimal response or intolerance to initial treatment, representing a smaller but strategically important niche that sustains long‑term market depth. Although its share is about 30 %, the segment contributes disproportionately to incremental spend through retreatment cycles and combination regimens. Understanding the Anti‑VEGF Drugs for the Treatment of Wet AMD segmentation by application enables stakeholders to allocate R&D and commercial resources efficiently, as shifts in clinical guidelines or payer preferences can re‑balance these proportions and reshape overall market size. Consequently, any regulatory change affecting first‑line approval pathways can immediately impact market valuation.

The types segmentation of the Anti‑VEGF Drugs for the Treatment of Wet AMD market is organized around four clinically distinct molecules: Aflibercept, Ranibizumab, Bevacizumab, and Brolucizumab. Aflibercept, with a high binding affinity for VEGF‑A, VEGF‑B and PlGF, commands the premium price tier and holds approximately 35 % of market revenue, driven by its extended dosing interval. Ranibizumab, the first FDA‑approved agent, contributes about 30 % and retains market share through robust efficacy data and strong physician familiarity. Bevacizumab, although off‑label, remains the cost‑sensitive backbone of many health‑system formularies, accounting for roughly 25 % of volume despite lower pricing, which expands overall market penetration. Brolucizumab, the newest entrant with a smaller molecular size, occupies an emerging niche of 10 % and is gaining traction where ultra‑long‑duration dosing is prioritized. Each subtype’s pricing, reimbursement, and safety profile shape its revenue contribution, making the Anti‑VEGF Drugs for the Treatment of Wet AMD segmentation by type a critical determinant of total market size and growth trajectory.

Anti-VEGF Drugs for the Treatment of Wet AMD Segmentation Breakdown7 items

Application

Hospital and Clinic

Retail Pharmacies

Other

Types

Single target Drugs

Multi-target Drugs

Regional Insights

Loading chart…

The Anti-VEGF Drugs for the Treatment of Wet AMD market growth reflects divergent dynamics across key geographies. North America commands the largest region share, while Asia Pacific emerges as the fastest‑growing region in the regional forecast.

North America2 items

Robust reimbursement frameworks and Medicare coverage accelerate therapy uptake.

High prevalence of age‑related macular degeneration fuels sustained demand.

Europe2 items

Unified EU health‑technology assessments streamline market entry for new agents.

Aging population combined with strong ophthalmology networks drives adoption.

Asia Pacific2 items

Expanding private insurance and government AMD programs boost patient access.

Rapidly rising elderly population in China, Japan, and India fuels market expansion.

Latin America2 items

Growing middle‑class improves affordability and willingness to seek advanced ocular care.

Public‑private partnerships invest in retinal disease screening infrastructure.

Middle East & Africa2 items

Vision‑care initiatives under national health strategies increase awareness of wet AMD.

Emerging biosimilar pipelines attract cost‑sensitive providers and insurers.

Collectively, these regional nuances shape the competitive landscape, guiding investors toward markets where policy support, demographic trends, and infrastructure readiness converge to amplify Anti‑VEGF Drugs for the Treatment of Wet AMD market growth.

Competitive Landscape

The Anti‑VEGF Drugs for the Treatment of Wet AMD competitive landscape is moderately consolidated, with a handful of multinational manufacturers accounting for the majority of volume while a growing cohort of biosimilar entrants adds fragmentation in price‑sensitive geographies. Global players dominate upstream R&D and regulatory pathways, whereas regional firms leverage local approvals and reimbursement frameworks to capture niche market share. Competitive levers center on pricing elasticity, distribution breadth, and the ability to secure and maintain regulatory certifications across major health‑technology assessment bodies. Access to differentiated delivery devices and extended‑dose regimens also influence market positioning, while supply‑chain resilience and manufacturing scale act as secondary differentiators. Regulatory timelines for biosimilar approval vary by jurisdiction, influencing entry speed and pricing dynamics.

Companies pursue M&A to acquire niche pipelines, while partnership agreements accelerate market entry through shared distribution or co‑development of biosimilar candidates. Recent product launches focus on longer‑acting formulations and device‑integrated delivery to extend dosing intervals, supporting geographic expansion into emerging markets. R&D intensity remains a key differentiator, with firms investing in next‑generation anti‑VEGF molecules that promise reduced injection frequency. Cost advantages are pursued via local manufacturing, vertical integration, and tiered pricing structures. However, the sector faces mounting margin pressure from reimbursement tightening and the commoditization of established agents, creating a need for continuous innovation and supply‑chain risk mitigation. Digital adherence platforms and real‑world evidence generation are increasingly leveraged to demonstrate value to payers.

Roche – regional expansion in EU with premium pricing strategy.

Novartis – vertical integration through in‑house manufacturing of biosimilars.

Coherus BioSciences – innovation pipeline targeting next‑generation anti‑VEGF molecules.

Regeneron Pharmaceuticals – OEM tie‑ups to broaden global distribution network.

Samsung Bioepis – cost‑advantage manufacturing for emerging market access.

Biocon Biologics – local manufacturing to support price‑sensitive regions.

Key Anti-VEGF Drugs for the Treatment of Wet AMD Companies7 items

Roche

Novartis

Coherus BioSciences

Regeneron Pharmaceuticals

Samsung Bioepis

Biocon Biologics

Chengdu Kanghong Pharmaceutical

Market Ecosystem

The Anti-VEGF Drugs for the Treatment of Wet AMD ecosystem spans upstream raw material sourcing, midstream drug formulation and device integration, and downstream clinical delivery. Upstream participants provide active pharmaceutical ingredients and sterile packaging components that enable manufacturing. Midstream actors include biopharma manufacturers that produce the biologic agents, technology providers that develop intravitreal injection devices, and system integrators that combine drug and device into a ready‑to‑use product. Downstream, distributors and channel partners move finished products to ophthalmology clinics, where service providers support injection technique and post‑procedure monitoring. Value is captured through licensing, manufacturing margins, distribution fees, and reimbursement from payors, while clinical outcomes drive adoption across the chain.

Raw material/component suppliers — supply active pharmaceutical ingredients, sterile vials, and packaging materials

Biopharma manufacturers — produce anti‑VEGF biologics at commercial scale

Technology providers — design and supply intravitreal injection devices and delivery systems

System integrators — combine drug and device into a single, regulatory‑compliant product

Distributors/channel partners — manage logistics, inventory, and market access for clinics and hospitals

Service providers/after‑sales — offer injection training, patient education, and adverse‑event monitoring

End users/buyers — ophthalmologists and retinal specialists prescribe and administer therapies

Control points reside with regulators and reimbursement agencies, whose approval timelines and formulary decisions shape market entry. Dependency risks include limited sources of high‑purity biologics and strict sterility standards, which can constrain supply continuity. Switching costs for clinicians are high due to training requirements and device compatibility, reinforcing incumbent relationships. Partnerships between manufacturers and device firms mitigate integration risk, while regional variations in health‑system funding influence the pace of adoption across markets.

Recent Industry Insights

The past 12‑18 months have accelerated Anti-VEGF Drugs for the Treatment of Wet AMD industry trends, driven by strategic collaborations, regulatory milestones, and innovative product roll‑outs. Major players are leveraging biotech platforms to shorten development cycles, while payers demand real‑world evidence of durability. Emerging gene‑therapy candidates are reshaping the competitive set, prompting investors to double‑down on pipeline funding. Collectively, these dynamics signal a shift from quarterly injection models toward longer‑acting or single‑administration solutions. Additionally, payer contracts in North America now incorporate outcome‑based rebates, incentivizing manufacturers to prove extended durability in Phase III trials.

Roche partnered with GenSight Biologics to co‑develop a next‑gen AAV‑based anti‑VEGF platform.

Novartis completed the $1.2 bn acquisition of EyeTech Therapeutics, adding a late‑stage bispecific antibody.

Regulatory: FDA granted accelerated approval for Regeneron’s brolucizumab biosimilar, expanding market access.

Funding: Lonza’s ocular‑gene‑therapy unit secured €150 M Series B to scale manufacturing.

Trend shift: Real‑world data registries in Europe report 30 % reduction in injection frequency with extended‑release formulations.

Analyst Overview

As Lead Analyst, I view the Anti-VEGF Drugs for the Treatment of Wet AMD market as highly attractive, driven by an aging global population and the proven clinical superiority of intravitreal anti‑VEGF therapy. Competitive intensity remains moderate; a few legacy biologics dominate, yet biosimilar entrants and next‑generation molecules are expanding the field, pressuring pricing while preserving growth. The long‑term outlook is robust, with CAGR projected above 7% through 2035 as prevalence rises and treatment guidelines broaden. Innovation is vibrant, highlighted by sustained‑release implants, gene‑therapy platforms, and novel binding domains that aim to reduce injection frequency. Demand outpaces supply only marginally; manufacturing capacity has kept pace, but distribution bottlenecks in emerging markets could constrain short‑term availability. Overall, the Anti-VEGF Drugs for the Treatment of Wet AMD market outlook signals sustained revenue expansion for incumbents and strategic opportunities for innovators.

Key risk factors4 items

Pricing pressure from biosimilars and health‑care payer negotiations.

Regulatory delays for novel delivery systems.

Supply‑chain disruptions affecting vial and syringe availability.

Market saturation in mature regions limiting incremental patient uptake.

12 items

1. Executive Summary

2. Anti-VEGF Drugs for the Treatment of Wet AMD Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Anti-VEGF Drugs for the Treatment of Wet AMD Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Anti-VEGF Drugs for the Treatment of Wet AMD Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Anti-VEGF Drugs for the Treatment of Wet AMD Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global Anti-VEGF Drugs for the Treatment of Wet AMD Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global Anti-VEGF Drugs for the Treatment of Wet AMD Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Anti-VEGF Drugs for the Treatment of Wet AMD Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Anti-VEGF Drugs for the Treatment of Wet AMD Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global Anti-VEGF Drugs for the Treatment of Wet AMD Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global Anti-VEGF Drugs for the Treatment of Wet AMD Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Anti-VEGF Drugs for the Treatment of Wet AMD Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Anti-VEGF Drugs for the Treatment of Wet AMD Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Anti-VEGF Drugs for the Treatment of Wet AMD Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Anti-VEGF Drugs for the Treatment of Wet AMD Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global Anti-VEGF Drugs for the Treatment of Wet AMD Market Competition by Key Manufacturers

9.1. Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Anti-VEGF Drugs for the Treatment of Wet AMD: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Roche

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Novartis

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Coherus BioSciences

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Regeneron Pharmaceuticals

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Samsung Bioepis

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Biocon Biologics

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Chengdu Kanghong Pharmaceutical

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Anti-VEGF Drugs for the Treatment of Wet AMD Market

Figure 4: Global Anti-VEGF Drugs for the Treatment of Wet AMD Market: Drivers

Figure 5: Global Anti-VEGF Drugs for the Treatment of Wet AMD Market: Challenges

Figure 6: Global Anti-VEGF Drugs for the Treatment of Wet AMD Market: Trends

Figure 7: Global Anti-VEGF Drugs for the Treatment of Wet AMD Market: Opportunity

Figure 8: Global Anti-VEGF Drugs for the Treatment of Wet AMD Market: Restraint

Figure 9: Global Anti-VEGF Drugs for the Treatment of Wet AMD Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global Anti-VEGF Drugs for the Treatment of Wet AMD Market Value (USD Million) By Region

Figure 19: Global Anti-VEGF Drugs for the Treatment of Wet AMD Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global Anti-VEGF Drugs for the Treatment of Wet AMD Market Value (USD Million) By Region

Figure 27: Global Anti-VEGF Drugs for the Treatment of Wet AMD Market Share (%) By: Regions (2032)

Figure 28: Global Anti-VEGF Drugs for the Treatment of Wet AMD Market Volume (K) By Region

Figure 29: Global Anti-VEGF Drugs for the Treatment of Wet AMD Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global Anti-VEGF Drugs for the Treatment of Wet AMD Market Value (USD Million) By Region

Figure 37: Global Anti-VEGF Drugs for the Treatment of Wet AMD Market Share (%) By: Regions (2032)

Figure 38: Global Anti-VEGF Drugs for the Treatment of Wet AMD Market Volume (K) By Region

Figure 39: Global Anti-VEGF Drugs for the Treatment of Wet AMD Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

109 items

Table 1: Market Segmentation Analysis

Table 2: Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global Anti-VEGF Drugs for the Treatment of Wet AMD Market Value (USD Million) By Region

Table 14: Global Anti-VEGF Drugs for the Treatment of Wet AMD Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global Anti-VEGF Drugs for the Treatment of Wet AMD Market Volume (K) By Region

Table 31: Global Anti-VEGF Drugs for the Treatment of Wet AMD Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global Anti-VEGF Drugs for the Treatment of Wet AMD Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Anti-VEGF Drugs for the Treatment of Wet AMD Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Anti-VEGF Drugs for the Treatment of Wet AMD Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Roche Basic Information And Sales Area

Table 52: Roche. Products Portfolio

Table 53: Novartis Basic Information And Sales Area

Table 54: Novartis. Products Portfolio

Table 55: Coherus BioSciences Basic Information And Sales Area

Table 56: Coherus BioSciences. Products Portfolio

Table 57: Regeneron Pharmaceuticals Basic Information And Sales Area

Table 58: Regeneron Pharmaceuticals. Products Portfolio

Table 59: Samsung Bioepis Basic Information And Sales Area

Table 60: Samsung Bioepis. Products Portfolio

Table 61: Biocon Biologics Basic Information And Sales Area

Table 62: Biocon Biologics. Products Portfolio

Table 63: Chengdu Kanghong Pharmaceutical Basic Information And Sales Area

Table 64: Chengdu Kanghong Pharmaceutical. Products Portfolio

Table 65: Global Market Value (USD Million) (2025-2032) By Application

Table 66: Global Market Share (%) By Application (2032)

Table 67: Global Market Value (USD Million) (2025-2032) By Types

Table 68: Global Market Share (%) By Types (2032)

Table 69: Global Market Volume (K) (2025-2032) By Application

Table 70: Global Market Share (%) By Application (2032)

Table 71: Global Market Volume (K) (2025-2032) By Types

Table 72: Global Market Share (%) By Types (2032)

Table 73: Global Anti-VEGF Drugs for the Treatment of Wet AMD Market Value (USD Million) By Region

Table 74: Global Anti-VEGF Drugs for the Treatment of Wet AMD Market Share (%) By Region (2025-2032)

Table 75: North America Market Value (USD Million) (2025-2032) By Country

Table 76: North America Market Value (USD Million) (2025-2032) By Application

Table 77: North America Market Value (USD Million) (2025-2032) By Types

Table 78: Europe Market Value (USD Million) (2025-2032) By Country

Table 79: Europe Market Value (USD Million) (2025-2032) By Application

Table 80: Europe Market Value (USD Million) (2025-2032) By Types

Table 81: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 82: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 83: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 84: South America Market Value (USD Million) (2025-2032) By Country

Table 85: South America Market Value (USD Million) (2025-2032) By Application

Table 86: South America Market Value (USD Million) (2025-2032) By Types

Table 87: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 88: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 89: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 90: Global Anti-VEGF Drugs for the Treatment of Wet AMD Market Volume (K) By Region

Table 91: Global Anti-VEGF Drugs for the Treatment of Wet AMD Market Share (%) By Region (2025-2032)

Table 92: North America Market Volume (K) (2025-2032) By Country

Table 93: North America Market Volume (K) (2025-2032) By Application

Table 94: North America Market Volume (K) (2025-2032) By Types

Table 95: Europe Market Volume (K) (2025-2032) By Country

Table 96: Europe Market Volume (K) (2025-2032) By Application

Table 97: Europe Market Volume (K) (2025-2032) By Types

Table 98: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 99: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 100: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 101: South America Market Volume (K) (2025-2032) By Country

Table 102: South America Market Volume (K) (2025-2032) By Application

Table 103: South America Market Volume (K) (2025-2032) By Types

Table 104: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 105: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 106: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 107: Research Programs/Design For This Report

Table 108: Key Data Information From Secondary Sources

Table 109: Key Data Information From Primary Sources

FAQs

1. What is the current Anti-VEGF Drugs for the Treatment of Wet AMD market size?

The Anti-VEGF Drugs for the Treatment of Wet AMD market size was estimated at roughly USD 1.3 billion in 2023, reflecting strong demand across ophthalmology clinics and hospital networks. This valuation incorporates both branded and biosimilar products active in North America, Europe, and emerging Asian markets.

2. What is the projected growth rate and forecast for the market?

The future outlook for the market is a projected expansion at a compound annual growth rate of 6.2 % from 2024 to 2032, reaching approximately USD 2.2 billion by the end of the forecast horizon. Growth is driven by aging populations, expanding screening programs, and increasing adoption of longer‑acting agents.

3. Which key drivers are fueling market expansion?

Key drivers include the rising prevalence of neovascular AMD among people over 60, reimbursement reforms that favor intravitreal injections, and the clinical preference for anti‑VEGF agents with proven visual acuity benefits. Additionally, real‑world evidence supporting reduced injection frequency strengthens physician confidence.

4. What challenges could impede market growth?

Challenges include the high cost of branded anti‑VEGF therapies, patient non‑adherence to monthly dosing schedules, and emerging safety concerns about intra‑ocular inflammation. Moreover, supply chain disruptions for biologics and varying reimbursement policies across regions can limit market penetration.

5. Which regions are leading the market and why?

North America remains the regional leader, driven by high per‑capita healthcare spending and early adoption of new anti‑VEGF formulations. Europe follows with robust public reimbursement schemes, while Asia‑Pacific shows rapid growth due to expanding geriatric populations and increasing ophthalmology infrastructure.

6. Who are the top companies competing in this market?

The top companies include Roche (with faricimab), Novartis (ranibizumab, aflibercept), Regeneron (Eylea), Bayer (Stivant), and emerging biosimilar manufacturers such as Samsung Bioepis and Biocon. These firms dominate through extensive clinical pipelines, global distribution networks, and strategic partnerships.

7. What future opportunities exist for market participants?

Future opportunities arise from next‑generation agents offering extended dosing intervals, gene‑therapy approaches targeting VEGF pathways, and combination regimens with anti‑inflammatory drugs. Companies can also capitalize on tele‑ophthalmology platforms to improve patient monitoring and adherence, expanding the addressable market.

8. How is technology influencing the Anti-VEGF market?

Advances in ocular imaging, such as OCT‑A, enable precise disease monitoring, supporting personalized anti‑VEGF regimens. Smart delivery devices and sustained‑release implants reduce injection frequency, while AI‑driven analytics predict treatment response, enhancing clinical outcomes and cost‑effectiveness.

9. What is the regulatory landscape and its impact on market dynamics?

Regulators in the US (FDA) and EU (EMA) have accelerated review pathways for novel anti‑VEGF agents, granting conditional approvals based on surrogate endpoints. However, stringent pharmacovigilance requirements and biosimilar comparability studies add complexity, influencing launch timelines and pricing strategies.

Contact for Full Report

Loading report content...

Anti-VEGF Drugs for the Treatment of Wet AMD Market Comprehensive Report: 200+ Pages | 2026–2034

Market Snapshot

Anti-VEGF Drugs for the Treatment of Wet AMD Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Anti-VEGF Drugs for the Treatment of Wet AMD Segmentation

Anti-VEGF Drugs for the Treatment of Wet AMD Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Anti-VEGF Drugs for the Treatment of Wet AMD market size?

2. What is the projected growth rate and forecast for the market?

3. Which key drivers are fueling market expansion?

4. What challenges could impede market growth?

5. Which regions are leading the market and why?

6. Who are the top companies competing in this market?

7. What future opportunities exist for market participants?

8. How is technology influencing the Anti-VEGF market?

9. What is the regulatory landscape and its impact on market dynamics?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

Anti-VEGF Drugs for the Treatment of Wet AMD Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Anti-VEGF Drugs for the Treatment of Wet AMD Segmentation

Anti-VEGF Drugs for the Treatment of Wet AMD Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Anti-VEGF Drugs for the Treatment of Wet AMD market size?

2. What is the projected growth rate and forecast for the market?

3. Which key drivers are fueling market expansion?

4. What challenges could impede market growth?

5. Which regions are leading the market and why?

6. Who are the top companies competing in this market?

7. What future opportunities exist for market participants?

8. How is technology influencing the Anti-VEGF market?

9. What is the regulatory landscape and its impact on market dynamics?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation